MARAVAI LIFESCIENCES HOLDINGS, INC.

(MRVI)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
26.88 USD   +2.28%
08/05MARAVAI LIFESCIENCES HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/05UBS Adjusts Maravai LifeSciences Holdings Price Target to $42 From $45, Maintains Buy Rating
MT
08/04MARAVAI LIFESCIENCES : Q2 2022 Maravai LifeSciences Earnings Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Maravai LifeSciences Holdings, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 02:40 PM

06/14/2022 | 05:40pm EDT
I'm Matt Sykes, the Life Science Tools and Diagnostics analyst at Goldman Sachs, and the pleasure of welcoming Maravai Life Sciences here this afternoon. Kevin Herde, the Executive Vice President...


© S&P Capital IQ 2022
All news about MARAVAI LIFESCIENCES HOLDINGS, INC.
08/05MARAVAI LIFESCIENCES HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
08/05UBS Adjusts Maravai LifeSciences Holdings Price Target to $42 From $45, Maintains Buy R..
MT
08/04MARAVAI LIFESCIENCES : Q2 2022 Maravai LifeSciences Earnings Presentation
PU
08/04Maravai LifeSciences Holdings Posts Higher Q2 Earnings, Revenue; Updates 2022 Outlook
MT
08/04TRANSCRIPT : Maravai LifeSciences Holdings, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS Reports Q2 EPS $0.54
MT
08/04Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS Posts Q2 Revenue $242.7M
MT
08/04CORRECTION : Maravai Lifesciences Reports Second Quarter 2022 Financial Results
GL
08/04CORRECTION : Maravai Lifesciences Reports Second Quarter 2022 Financial Results
GL
08/04MARAVAI LIFESCIENCES : REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS - Form 8-K
PU
More news
Analyst Recommendations on MARAVAI LIFESCIENCES HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 903 M - -
Net income 2022 305 M - -
Net cash 2022 190 M - -
P/E ratio 2022 23,1x
Yield 2022 0,37%
Capitalization 3 536 M 3 536 M -
EV / Sales 2022 3,70x
EV / Sales 2023 4,95x
Nbr of Employees 550
Free-Float 51,4%
Chart MARAVAI LIFESCIENCES HOLDINGS, INC.
Duration : Period :
Maravai LifeSciences Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MARAVAI LIFESCIENCES HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 26,88 $
Average target price 35,75 $
Spread / Average Target 33,0%
EPS Revisions
Managers and Directors
Carl W. Hull Chairman & Chief Executive Officer
Kevin M. Herde Chief Financial Officer & Executive Vice President
Mike Houston Chief Science Officer
Peter Michael Leddy Chief Administrative Officer & Executive VP
Anat Ashkenazi Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MARAVAI LIFESCIENCES HOLDINGS, INC.-35.85%3 536
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093